Stock Movers Nvidia Down, General Mills Lower, Eli Lilly Up on GLP-1 Pill Performance
Sep 17, 2025
Nvidia's shares tumble as China's internet regulator halts purchases of their AI chips, disappointing the CEO. General Mills sees a drop in North American sales despite beating EPS expectations, as consumers cook at home amid inflation. In contrast, Eli Lilly's new oral GLP-1 diabetes drug shows impressive results, outperforming its competitor in weight loss and blood sugar control. Doctors are optimistic about its potential to make diabetes treatment more accessible and affordable.
AI Snips
Chapters
Transcript
Episode notes
China Restricts Nvidia Chip Orders
- China ordered big tech firms to stop buying NVIDIA's RTX Pro 6000D chips, hitting NVDA shares down about 2.5%.
- Jensen Huang said he's "disappointed" and will be patient in responding to the restriction.
General Mills Sees Mixed Sales Signals
- General Mills beat first-quarter adjusted EPS at $0.86 but shares barely moved.
- The company cited more home cooking among value-conscious consumers, lifting rice and beans sales while overall North America retail volumes fell.
Eli Lilly's Oral GLP-1 Outperforms Rival
- Eli Lilly's experimental oral GLP-1 tablet produced greater weight loss and better glucose control than Novo Nordisk's pill in a head-to-head trial.
- Patients on Lilly's drug lost 8.2% body weight versus 5.3% on Novo's at 52 weeks, and doctors said oral dosing could expand access.